Kim, Su-Hyun <br/><br/>
Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy.  [electronic resource] 

 -  JAMA neurology  04 2017 
 - 482 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>2168-6157 
<br/><br/><label>Standard No.: </label>10.1001/jamaneurol.2016.5933  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Humans<br/>Immunologic Factors<br/>Neuromyelitis Optica<br/>Rituximab